Our results also support the central role of CD59 in the modulation of AQP4-IgG-initiated complement injury and hence suggest the potential therapeutic benefit in NMO of upregulation of astrocyte CD59 or alternative complement regulator proteins by pharmacological or other means. This evidence concerns the gene AQP4 and neuromyelitis optica.